Latest:
Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL
Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ben Levy, MD, The Johns Hopkins University School of Medicine
Latest:
Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care
A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.
Antoinette Tan, MD, MHS
Antoinette Tan, MD, MHS, is chief of Breast Medical Oncology and co-director of the Phase I Program at Levine Cancer Institute, Carolinas HealthCare System; chief of Medical Oncology at Carolinas Medical Center-Pineville; and a Clinical Professor in the Department of Medicine at the University of North Carolina
Latest:
Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer
Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.
Hira Mian, MD
Hira Mian, MD, MSc, FRCPC is an Associate Professor in the Department of Oncology at McMaster University.
Latest:
Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.
Megan Hollasch
Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication
Latest:
Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer
Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.
Marc S. Raab, MD
Marc S. Raab is a physician-scientist and Professor of Medicine at the Heidelberg University Medical Center (HUMC).
Latest:
Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma
Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.
Genmab and AbbVie Sponsored Content; OncLive Article with Tahi Ahmadi and Asud Khaliq
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Thor R. Halfdanarson, MD
Latest:
Integrating Cabozantinib Into the NET Treatment Landscape
Panelists discuss cabozantinib’s role in the neuroendocrine tumor treatment landscape, emphasizing its utility as a third-line option post somatostatin analogues and systemic therapy, while highlighting its efficacy in heavily pretreated patients, the importance of careful sequencing—especially relative to PRRT—and considerations for ideal patient selection, including those with grade 3 well-differentiated tumors.